Phase 2Completed
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
- Sponsor
- BPGbio (Industry)
- Enrolment
- 45 enrolled
- Conditions
- Pancreatic Cancer
- Interventions
- BPM31510 Nanosuspension Injection; Gemcitabine
- Ages
- adults, older adults
- Registry
- NCT02650804
From the registry
This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered over 144-hours (two 72-hour 110mg/Kg doses) continuous intravenous (IV) infusion in combination with gemcitabine in advanced pancreatic cancer patients as 2nd / 3rd line therapy. The study will enroll up to 25 patients in the US and Europe.
Primary outcomes
- Treatment Response